MX2018007794A - Formulaciones de derivados de fosforamidato de fármacos de nucleósidos. - Google Patents

Formulaciones de derivados de fosforamidato de fármacos de nucleósidos.

Info

Publication number
MX2018007794A
MX2018007794A MX2018007794A MX2018007794A MX2018007794A MX 2018007794 A MX2018007794 A MX 2018007794A MX 2018007794 A MX2018007794 A MX 2018007794A MX 2018007794 A MX2018007794 A MX 2018007794A MX 2018007794 A MX2018007794 A MX 2018007794A
Authority
MX
Mexico
Prior art keywords
formulations
phosphoramidate derivatives
nucleoside drugs
protides
alaninyl
Prior art date
Application number
MX2018007794A
Other languages
English (en)
Inventor
Griffith Hugh
Kennovin Gordon
Original Assignee
NuCana plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NuCana plc filed Critical NuCana plc
Publication of MX2018007794A publication Critical patent/MX2018007794A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)

Abstract

Esta invención se refiere a formulaciones farmacéuticas y estrategias de formulación de prótidos (derivados de fosforamidato de nucelósidos) y, en particular, prótidos útiles en el tratamiento de cáncer tal como NUC-3373 (5-fluoro-2'-desoxiuridina-5'-O-[1-naptil (benzoxi-L-alaninil)] fosfato) y NUC-7738 (3´-desoxiadenosina-5´-O-[fenil(benciloxi-L-al aninil)] fosfato); en particular, la invención se refiere a formulaciones que comprenden un disolvente aprótico polar, por ejemplo dimetilacetamida (DMA).
MX2018007794A 2015-12-23 2016-12-21 Formulaciones de derivados de fosforamidato de fármacos de nucleósidos. MX2018007794A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1522764.8A GB201522764D0 (en) 2015-12-23 2015-12-23 Formulations of phosphate derivatives
PCT/GB2016/054025 WO2017109491A1 (en) 2015-12-23 2016-12-21 Formulations of phosphoramidate derivatives of nucleoside drugs

Publications (1)

Publication Number Publication Date
MX2018007794A true MX2018007794A (es) 2019-07-01

Family

ID=55311533

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018007794A MX2018007794A (es) 2015-12-23 2016-12-21 Formulaciones de derivados de fosforamidato de fármacos de nucleósidos.
MX2021010601A MX2021010601A (es) 2015-12-23 2018-06-22 Formulaciones de derivados de fosforamidato de farmacos de nucleosidos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021010601A MX2021010601A (es) 2015-12-23 2018-06-22 Formulaciones de derivados de fosforamidato de farmacos de nucleosidos.

Country Status (20)

Country Link
US (3) US20180369266A1 (es)
EP (1) EP3393453A1 (es)
JP (2) JP6913095B2 (es)
KR (1) KR20180091919A (es)
CN (1) CN108697636A (es)
AU (2) AU2016375866B2 (es)
BR (2) BR122023000551B1 (es)
CA (1) CA3008751C (es)
CL (1) CL2018001672A1 (es)
EA (2) EA037320B1 (es)
GB (1) GB201522764D0 (es)
HK (1) HK1255108A1 (es)
IL (1) IL260008A (es)
MA (1) MA44117A (es)
MX (2) MX2018007794A (es)
MY (1) MY196741A (es)
PH (1) PH12018501341A1 (es)
SA (1) SA518391858B1 (es)
SG (2) SG10202008554RA (es)
WO (1) WO2017109491A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0317009D0 (en) 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
RS54776B1 (sr) 2011-03-01 2016-10-31 Nucana Biomed Ltd Fosforoamidatni derivati 5-fluoro-2'-dezoksiuridina za upotrebu u tretmanu kancera
NO3119794T3 (es) 2014-06-25 2018-03-10
EP3683225A1 (en) 2014-11-28 2020-07-22 Nucana PLC New 2' and/or 5' amino-acid ester phosphoramidate 3'-deoxy adenosine derivatives as anti-cancer compounds
GB201609600D0 (en) 2016-06-01 2016-07-13 Nucuna Biomed Ltd Cancer treatments
GB201709471D0 (en) 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives
GB201713916D0 (en) * 2017-08-30 2017-10-11 Nucana Biomed Ltd Treatment regimens
CN110840907B (zh) * 2019-08-16 2022-11-25 南京医科大学 一类自由基敏感的尿嘧啶类ProTide前药及其药物用途
WO2023218202A2 (en) 2022-05-12 2023-11-16 NuCana plc Cancer treatment

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003500368A (ja) * 1999-05-24 2003-01-07 ソーナス ファーマシューティカルス，インコーポレイテッド 溶解度が不十分な薬剤のためのエマルジョンビヒクル
GB0412866D0 (en) 2004-06-09 2004-07-14 Novartis Ag Organic compounds
AU2006208108A1 (en) 2005-01-27 2006-08-03 Erimos Pharmaceuticals Llc Oral formulations for delivery of catecholic butanes including NDGA compounds
GB0505781D0 (en) * 2005-03-21 2005-04-27 Univ Cardiff Chemical compounds
JP5528708B2 (ja) 2006-02-09 2014-06-25 参天製薬株式会社 安定な製剤ならびにそれらを調製および使用する方法
WO2010081082A2 (en) * 2009-01-09 2010-07-15 University College Of Cardiff Consultants Limited Phosphoramidate derivatives of guanosine nucleoside compounds for treatment of viral infections
WO2010091386A2 (en) 2009-02-06 2010-08-12 Rfs Pharma, Llc Purine nucleoside monophosphate prodrugs for treatment of cancer and viral infections
KR101201956B1 (ko) 2009-03-18 2012-11-19 신동헌 파카스트리사민을 유효성분으로 함유하는 과증식성 피부질환과 악성흑색종의 예방 또는 치료용 약학적 조성물
AU2010226466A1 (en) 2009-03-20 2011-10-20 Alios Biopharma, Inc. Substituted nucleoside and nucleotide analogs
AP3584A (en) 2010-09-22 2016-02-09 Alios Biopharma Inc Substituted nucleotide analogs
RS54776B1 (sr) 2011-03-01 2016-10-31 Nucana Biomed Ltd Fosforoamidatni derivati 5-fluoro-2'-dezoksiuridina za upotrebu u tretmanu kancera
EP2776438A4 (en) 2011-11-10 2015-04-29 Inhibitex Inc SUBSTITUTED PURIN NUCLEOSIDES, PHOSPHORAMIDATE AND PHOSPHORDIAMIDATE DERIVATIVES FOR THE TREATMENT OF VIRUS INFECTIONS
US9107943B2 (en) 2012-01-20 2015-08-18 Aratana Therapeutics Nv Eye drop composition
US9125805B2 (en) 2012-06-27 2015-09-08 Xeris Pharmaceuticals, Inc. Stable formulations for parenteral injection of small molecule drugs
CN105163719B (zh) * 2013-03-11 2019-03-08 度瑞公司 包含高粘度液体载体的可注射控制释放组合物
NO3119794T3 (es) * 2014-06-25 2018-03-10
EP3683225A1 (en) * 2014-11-28 2020-07-22 Nucana PLC New 2' and/or 5' amino-acid ester phosphoramidate 3'-deoxy adenosine derivatives as anti-cancer compounds
GB201609600D0 (en) 2016-06-01 2016-07-13 Nucuna Biomed Ltd Cancer treatments
GB201709471D0 (en) 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives
GB201713916D0 (en) 2017-08-30 2017-10-11 Nucana Biomed Ltd Treatment regimens
GB201715011D0 (en) 2017-09-18 2017-11-01 Nucana Biomed Ltd Floxuridine synthesis

Also Published As

Publication number Publication date
AU2022211797A1 (en) 2022-08-25
SA518391858B1 (ar) 2022-10-30
JP2021165310A (ja) 2021-10-14
WO2017109491A1 (en) 2017-06-29
HK1255108A1 (zh) 2019-08-02
CL2018001672A1 (es) 2019-02-01
EA201891471A1 (ru) 2018-12-28
MY196741A (en) 2023-05-03
SG10202008554RA (en) 2020-10-29
US20180369266A1 (en) 2018-12-27
JP2018538342A (ja) 2018-12-27
AU2022211797B2 (en) 2024-04-04
MX2021010601A (es) 2021-09-28
EA037320B1 (ru) 2021-03-11
US11786544B2 (en) 2023-10-17
PH12018501341A1 (en) 2019-02-18
GB201522764D0 (en) 2016-02-03
BR122023000551B1 (pt) 2023-12-05
IL260008A (en) 2018-07-31
CA3008751C (en) 2023-10-03
BR112018012951A2 (pt) 2018-12-11
AU2016375866B2 (en) 2022-06-09
BR112018012951B1 (pt) 2023-12-12
JP6913095B2 (ja) 2021-08-04
US20220031728A1 (en) 2022-02-03
KR20180091919A (ko) 2018-08-16
CA3008751A1 (en) 2017-06-29
MA44117A (fr) 2021-03-31
US20240082287A1 (en) 2024-03-14
EP3393453A1 (en) 2018-10-31
CN108697636A (zh) 2018-10-23
SG11201805318SA (en) 2018-07-30
EA202190058A1 (ru) 2021-06-30
AU2016375866A1 (en) 2018-07-05

Similar Documents

Publication Publication Date Title
MX2021010601A (es) Formulaciones de derivados de fosforamidato de farmacos de nucleosidos.
PH12018502606A1 (en) Phosphoramidate nucleoside derivatives as anticancer agents
PH12015502799A1 (en) Substituted nucleosides, nucleotides and analogs thereof
MX2022009737A (es) Sistema de impresion tridimensional y ensamblaje de equipo.
PH12016502552A1 (en) Formulation comprising a gemcitabine-prodrug
NZ730803A (en) Methods for the preparation of ribosides
PH12014502094B1 (en) Substituted nucleosides, nucleotides and analogs thereof
GEP20237502B (en) B-D-2'-DEOXY-2'a-FLUORO-2'-B-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT
CR20200192A (es) Métodos y composiciones para la producción de nucleósido trifosfatos y ácidos ribonucleicos
PH12018500263A1 (en) Pyrrolopyrimidine nucleosides and analogs thereof useful as antiviral agents
CY1122074T1 (el) Νεα παραγωγα 3'-δεοξυαδενοσινης του φωσφοραμαδικου εστερα toy 2' και/η 5' aminoξεος ως αντικαρκινικες ενωσεις
CL2013002517A1 (es) Compuestos derivados de fosforoamidato de 5-fluoro-2'-desoxiuridina; procedimiento de preparacion; composicion farmaceutica que los comprende; su uso en el tratamiento o profilaxis del cancer.
EA201691554A1 (ru) 4'-дифторметилзамещенные производные нуклеозидов в качестве ингибиторов репликации рнк вируса гриппа
EP3512863A4 (en) 2 '-SUBSTITUTE-N6-PURINE NUCLEOTID SUBSTITUTED FOR THE TREATMENT OF RNA VIRUSES
MX2020004454A (es) Manufactura de productos de interpolimero de etileno a una mayor tasa de produccion.
PH12015502589A1 (en) 4`-azido, 3`-deoxy-3`-fluoro substituted nucleoside derivatives
MX2018011970A (es) Formas sólidas de (1s,4s)-4-(2-(((3s,4r)-3-fluorotetrahidro-2h-pir an-4-il)amino)-8-((2,4,6-triclorofenilo)amino)-9h-purin-9-il)-1-m etilciclohexano-1-carboxamida y métodos para utilizarlas.
WO2020121123A3 (en) Cyclopentyl nucleoside analogs as anti-virals
EP3192799A4 (en) 5'-position dibenzyl phosphoric acid ester of 5-azacytidine or 2'-deoxy body thereof
MX2021006992A (es) Análogos de nucleósidos de ciclobutilo como antivirales.
MX2021009278A (es) Nucleosidos antivirales y derivados de estos.
PH12020500022A1 (en) Salt of (ss)-adenosyl methionine with inositol hexaphosphate, and process for the preparation thereof
EP3730504A4 (en) LIVER RELEASE BASED COMPOUND OF CYTARABINE PRODRUG AND NUCLEOSIDE CYCLIC PHOSPHATE AND USE
EA201990541A1 (ru) Состав, содержащий пролекарство гемцитабина
TH166778B (th) องค์ประกอบโอลิโกนิวคลีโอไทด์และวิธีการในการทำองค์ประกอบนี้